Clinicians must recognize the broad and atypical clinical spectrum of ATTRwt to correctly identify patients for emerging disease-modifying treatments.
The clinical spectrum of ATTRwt is heterogeneous and differs from the classic phenotype: women are affected in a significant proportion; asymmetric LV hypertrophy and impaired LVEF are not rare and only a minority have low QRS voltages. Clinicians should be aware of the broad clinical spectrum of ATTRwt to correctly identify an entity for which a number of disease-modifying treatments are under investigation.
González-López et al. (Mon,) studied this question.